MetaCap

Evotec (EVO) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Shattuck Labs (STTK) has outperformed Evotec (EVO) over the past year, gaining 119.7% versus a loss of 55.6%. Over five years, STTK leads with a -52.0% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $454.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVO-55.56%STTK+119.70%
+315%+121%-73%
Nov 21, 20251 yearNov 20, 2026
EVO-94.42%STTK-52.55%
+20%-40%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVO versus STTK key metrics
MetricEVOSTTK
Share price$1.32$4.46
Market cap$469.11M$454.22M
1-day change-8.97%-1.98%
YTD return-57.14%+22.19%
1-year return-55.56%+119.70%
5-year return-94.44%-51.99%
EPS (TTM)$-0.59$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.00M
Revenue growth (YoY)—-82.52%
Net income (latest FY)—$-48.81M
Operating margin—-5150.80%
Net margin—-4880.90%
52-week high$3.87$8.33
52-week low$1.32$1.93
Distance from 52-week high-65.89%-46.46%
Analyst consensusbuystrong_buy
Avg. price target upside+237.12%+245.29%
Average volume109.16K1.20M
Shares outstanding355.39M101.84M
Employees4,37940
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STTK has outperformed EVO by 175.3 percentage points over the past year.

About Evotec

EVO stock →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics.

Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

EVO vs STTK FAQ

Which is bigger, Evotec or Shattuck Labs?

Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $454.22M for Shattuck Labs (STTK).

Which stock has performed better over the past year, EVO or STTK?

STTK returned +119.70% over the past 12 months, compared with -55.56% for EVO (price return, excluding dividends). Past performance does not predict future results.

Are Evotec and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons